PMID- 24174373
OWN - NLM
STAT- MEDLINE
DCOM- 20140514
LR  - 20210816
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 134
IP  - 10
DP  - 2014 May 15
TI  - The validation of estrogen receptor 1 mRNA expression as a predictor of outcome 
      in patients with metastatic non-small cell lung cancer.
PG  - 2314-21
LID - 10.1002/ijc.28571 [doi]
AB  - The prognostic role of estrogen receptors in lung cancer is not validated. 
      Results from patients with early stage non-small lung cancer patients indicate a 
      prognostic role of estrogen receptor 1 (ESR1) mRNA expression in these patients. 
      Automated RNA extraction from paraffin and RT-quantitative PCR was used for 
      evaluation of tumoral ESR1 and progesterone receptor (PGR) mRNA expression. The 
      test cohort consisted of 31 patients with advanced or metastatic non-small cell 
      lung cancer (NSCLC) patients, treated in a first-line registry trial. For 
      validation, 53 patients from a randomized multicentre first-line study with 
      eligible tumor samples were evaluated. There was no significant correlation of 
      ESR1 expression with clinical characteristics. ESR1 high expression was of 
      significant positive prognostic value in the training set with a median overall 
      survival (OS) of 15.9 versus 6.2 months for high versus low ESR1 expression 
      patients (p = 0.0498, HR 0.39). This could be confirmed in the validation cohort 
      with a median OS of 10.9 versus 5.0 months in ESR1 high versus low patients, 
      respectively (p = 0.0321, HR 0.51). In the multivariate analysis adjusted for 
      histological subtype, gender, age and performance status, ESR1 expression 
      remained an independent prognostic parameter for survival in both cohorts. In 
      contrast to ESR1, PGR expression was not able to separate prognostic groups or to 
      predict outcome significantly (for OS; p = 0.94). Our study shows that ESR1 mRNA 
      as assessed by qPCR represents a reliable method for detecting ESR1 expression in 
      NSCLC and that ESR1 expression is an independent prognostic factor in metastatic 
      NSCLC.
CI  - (c) 2013 UICC.
FAU - Atmaca, Akin
AU  - Atmaca A
AD  - Department of Hematology and Oncology, Krankenhaus Nordwest, Frankfurt am Main, 
      Germany.
FAU - Al-Batran, Salah-Eddin
AU  - Al-Batran SE
FAU - Wirtz, Ralph Markus
AU  - Wirtz RM
FAU - Werner, Dominique
AU  - Werner D
FAU - Zirlik, Sabine
AU  - Zirlik S
FAU - Wiest, Gunther
AU  - Wiest G
FAU - Eschbach, Corinna
AU  - Eschbach C
FAU - Claas, Silke
AU  - Claas S
FAU - Hartmann, Arndt
AU  - Hartmann A
FAU - Ficker, Joachim Hans
AU  - Ficker JH
FAU - Jager, Elke
AU  - Jager E
FAU - Brueckl, Wolfgang Michael
AU  - Brueckl WM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20131114
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (ESR1 protein, human)
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Progesterone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/*genetics
MH  - Estrogen Receptor alpha/*genetics
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*genetics
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasm Metastasis
MH  - Paraffin Embedding/methods
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - RNA, Messenger/genetics/metabolism
MH  - Receptors, Progesterone/genetics
MH  - Reproducibility of Results
MH  - Reverse Transcriptase Polymerase Chain Reaction/methods
MH  - Time Factors
OTO - NOTNLM
OT  - estrogen receptor 1
OT  - metastatic
OT  - non-small cell lung cancer
OT  - progesterone receptor
EDAT- 2013/11/01 06:00
MHDA- 2014/05/16 06:00
CRDT- 2013/11/01 06:00
PHST- 2013/05/23 00:00 [received]
PHST- 2013/09/10 00:00 [revised]
PHST- 2013/10/07 00:00 [accepted]
PHST- 2013/11/01 06:00 [entrez]
PHST- 2013/11/01 06:00 [pubmed]
PHST- 2014/05/16 06:00 [medline]
AID - 10.1002/ijc.28571 [doi]
PST - ppublish
SO  - Int J Cancer. 2014 May 15;134(10):2314-21. doi: 10.1002/ijc.28571. Epub 2013 Nov 
      14.